FOLH1 and prostate carcinoma: Thus, based on these findings in a selective cohort of patients with exclusion of patients with 68Ga-PSMA PET-positive lymph node or distant metastases a priori, the current analysis supports the recommendations by several guidelines on prostate cancer that PSMA PET/CT should be performed in patients with PSA >0.2 ng/ml and sRT should not be postponed until a PSMA PET-positive result is observed (3, 21).